Today, Belluscura announced progress in the distribution of their portable oxygen devices designed to help millions of people that suffer from Chronic Obstructive Pulmonary Disease (COPD).
As a portfolio company of Tekcapital, Belluscura has the potential to save and improve the lives of millions of people by taking a foot hold in the Portable Oxygen Concentrator Market.
Having listed in London in 2021, the company recorded its first sales in the latter half of the year and today said sales had increased 34% in the first half of this year.
In addition to revealing their latest sales figures, Belluscura unveiled a significant agreement with a leading distributor in the US which promises to help push further sales growth.
Belluscura has used their formative period as a London listed company to improve their manufacturing capabilities and said they expect to reduce production costs by 10% going forward as they bring manufacturing in-house.
The company is well funded with $11.3 million net cash at the end of June 2022.
Belluscura Innovation
Belluscura continue to drive forward innovations with the introduction of technology that allows users to connect to devices such as iPhones and FITBITS to help track their oxygen uses.